Bevacizumab (Avastin) eye drops inhibit corneal neovascularization

被引：159

作者：

Bock, Felix ^{[1
]}

Koenig, Yanyan ^{[1
]}

Kruse, Friedrich ^{[1
]}

Baier, Martin ^{[1
]}

Cursiefen, Claus ^{[1
]}

机构：

[1] Univ Erlangen Nurnberg, Dept Ophthalmol, Univ Pharm, D-91054 Erlangen, Germany

来源：

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY | 2008年 / 246卷 / 02期

关键词：

cornea; angiogenesis; inhibition; bevacizumab; eye drops;

D O I：

10.1007/s00417-007-0684-4

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Background To analyze the ability of bevacizumab (Avastin) eye drops to inhibit corneal neovascularization. Design: interventional case series involving five patients (age: 42 +/- 14 years). Methods Patients with aggressive corneal neovascularisation not responding to conventional therapy were treated with bevacizumab (Avastin) eye drops (5x/day; 5 mg/ml) for 0.5 to 6 months (mean: 3.6 +/- 2; four patients with limbal stem cell deficiency [three due to chemical burns and one inherited] and one after perforating keratoplasty). Results Bevacizumab eye drops were well tolerated without obvious corneal side-effects. All five patients showed a reduction in the neovascularized area (decrease 48 +/- 28%; 13-75%). Conclusion Bevacizumab eye drops seem to inhibit corneal neovascularization without obvious corneal epithelial side-effects.

引用

页码：281 / 284

页数：4

共 11 条

[1] Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model [J].

Bakri, Sophie J. ;

Cameron, J. Douglas ;

McCannel, Colin A. ;

Pulido, Jose S. ;

Marler, Ronald J. .

AMERICAN JOURNAL OF OPHTHALMOLOGY, 2006, 142 (01) :162-164

[2] Inhibition of angiogenesis in the anterior chamber of the eye [J].

Bock, F. ;

Koenig, Y. ;

Dietrich, T. ;

Zimmermann, P. ;

Baier, M. ;

Cursiefen, C. .

OPHTHALMOLOGE, 2007, 104 (04) :336-344

[3] Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis [J].

Bock, Felix ;

Onderka, Jasmine ;

Dietrich, Tina ;

Bachmann, Bjorn ;

Kruse, Friedrich E. ;

Paschke, Matthias ;

Zahn, Grit ;

Cursiefen, Claus .

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2007, 48 (06) :2545-2552

[4] Corneal neovascularization [J].

Chang, Jin-Hong ;

Gabison, Eric E. ;

Kato, Takuji ;

Azar, Dimitri T. .

CURRENT OPINION IN OPHTHALMOLOGY, 2001, 12 (04) :242-249

[5] Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival [J].

Cursiefen, C ;

Cao, JT ;

Chen, L ;

Liu, Y ;

Maruyama, K ;

Jackson, D ;

Kruse, FE ;

Wiegand, SJ ;

Dana, MR ;

Streilein, JW .

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2004, 45 (08) :2666-2673

[6] Pericyte recruitment in human corneal angiogenesis:: an ultrastructural study with clinicopathological correlation [J].

Cursiefen, C ;

Hofmann-Rummelt, C ;

Küchle, M ;

Schlötzer-Schrehardt, U .

BRITISH JOURNAL OF OPHTHALMOLOGY, 2003, 87 (01) :101-106

[7] Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor α, and transforming growth factor β1 in human corneas with neovascularization [J].

Cursiefen, C ;

Rummelt, C ;

Küchle, M .

CORNEA, 2000, 19 (04) :526-533

[8] Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision [J].

Cursiefen, Claus ;

Chen, Lu ;

Saint-Geniez, Magali ;

Hamrah, Pedram ;

Jin, Yiping ;

Rashid, Saadia ;

Pytowski, Bronislaw ;

Persaud, Kris ;

Wu, Yan ;

Streilein, J. Wayne ;

Dana, Reza .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (30) :11405-11410

[9] Subconjunctival bevacizumab for corneal neovascularization [J].

Erdurmus, Mesut ;

Totan, Yuksel .

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2007, 245 (10) :1577-1579

[10] Endothelin-1 and ETA/ETB receptor protein and mRNA -: Expression in normal and vascularized human corneas [J].

Kuhlmann, A ;

Amann, K ;

Schlötzer-Schrehardt, U ;

Kruse, FE ;

Cursiefen, C .

CORNEA, 2005, 24 (07) :837-844

← 1 2 →